Skip to main content
NAMS
NASDAQ Life Sciences

NewAmsterdam Pharma Posts $19.2M in Q3 Revenue

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$20.24
Mkt Cap
$2.379B
52W Low
$19.13
52W High
$42.205
52W Position info
5.8% above low
Off High info
52% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

NAMS is trading near its 52-week low of $19.13 (5.8% above the low).

Summary

NewAmsterdam Pharma reported third-quarter revenue of $19.2M, its first top-line print since the European Commission approved Ubeslo and Evlarco in September. That approval is the launch engine behind the revenue line, so the number is the first read on how quickly the EU rollout is converting. The quarter's loss per share came in at 14c, and research and development expenses were $39.4M. The company is still burning cash — Q2's loss widened to $64.1M on higher R&D spend, against a $678M cash balance — so revenue scale matters less than the burn rate and any update to the funding runway. The headline carries no guidance and no year-over-year comparison, so the quarter's quality is unclear from this alone.

At the time of this announcement, NAMS was trading at $20.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $19.13 to $42.21. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

NAMS - Latest Insights

NAMS
Nov 04, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $18.54 info
Change: -$2.15 (-10%) info
Market Cap: $2.224B info
NAMS
Sep 29, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.71
Real-time Price: $18.54 info
Change: -$5.17 (-22%) info
Market Cap: $2.224B info
NAMS
Sep 22, 2026, 4:58 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.32
Real-time Price: $18.54 info
Change: -$4.78 (-20%) info
Market Cap: $2.224B info
NAMS
Sep 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $22.82
Real-time Price: $18.54 info
Change: -$4.28 (-19%) info
Market Cap: $2.224B info
NAMS
Aug 05, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.52
Real-time Price: $18.54 info
Change: -$8.98 (-33%) info
Market Cap: $2.224B info